Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956096 | 0.88 | ALPL (0.46) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL29546106 | 0.85 | NPC1 (0.62) | SMN1; SMN2MAPTPOLBALDH1A1GAA | |
| SCHEMBL1431346 | 0.85 | NPC1 (0.62) | SMN1; SMN2MAPTPOLBALDH1A1GAA | |
| SCHEMBL32665157 | 0.84 | MEP1B (0.44) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL2795240 | 0.82 | ALDH1A1 (0.49) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL8688873 | 0.81 | PLK1 (0.48) | SMN1; SMN2MAPTPOLBALDH1A1GAA | |
| SCHEMBL3949534 | 0.81 | ALDH1A1 (0.51) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL20302081 | 0.80 | ALPL (0.45) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL30458422 | 0.80 | ALPL (0.45) | ALPLALPIALPGSMN1; SMN2MAPT | |
| SCHEMBL1428912 | 0.79 | KMT2A (0.53) | ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292523-A | Selective butyrylcholine esterase inhibitor or medicinal salt thereof, and preparation method and application thereof | 中国药科大学 | 2021-08-24 | — | — | CN | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009138707-A9 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009097233-A9 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1635837-B1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1931639-A2 | PROCESS | Astra Zeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034183-A2 | PROCESS FOR THE PREPARATION OF 4-AMINOPYRAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1635837-A1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004105764-A1 | (3- ((QUINAZOLIN-4-YL) AMINO )-1H-PYRAZOL-1-YL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | ALPL 2410/4885ALPI 1205/4885ALPG 750/4885 |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | ALPL 4110/4885ALPI 3754/4885ALPG 4849/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | ALPL 4209/4885ALPI 3046/4885ALPG 4366/4885 |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | CDK19, CDK16, AURKC | ALPL 1675/4885ALPI 1271/4885ALPG 3232/4885 |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | CYP3A4, CYP3A43, CYP3A5 | ALPL 2799/4885ALPI 1861/4885ALPG 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.